

## Claims

We claim:

- 5           1.           A composition for inhibiting protein activated receptor activity comprising a protein, peptide, biomolecule or active fragment thereof.
- 10           2.           The composition of Claim 1 wherein the protein activated receptor comprises PAR-1, PAR-2, PAR-3 or PAR-4.
- 15           3.           The composition of Claim 1 wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1), LIGKV (SEQ ID NO:2), KGIL (SEQ ID NO:3), KGI (SEQ ID NO:4), AGI (SEQ ID NO:5), IGA (SEQ ID NO:6), KGA (SEQ ID NO:7), KGA (SEQ ID NO:8), KAI (SEQ ID NO:9), IAK (SEQ ID NO:10), RGI (SEQ ID. NO:11), IGR (SEQ ID NO:12), Dab-GI (SEQ ID NO:13 ), Dap-GI (SEQ ID NO:14), IG-Dab (SEQ ID NO:15 ), IG-Dap (SEQ ID NO:16), LIG-Dab (SEQ ID NO:17), Dab-GIL (SEQ ID NO:18), LIG-Dap (SEQ ID NO:19), Dap-GIL (SEQ ID NO:20), LIG-Orn (SEQ ID NO:21), Orn-GIL (SEQ ID: 22), Orn-GI (SEQ ID NO:23), IG-Orn (SEQ ID NO:24), ENMD 545, ENMD 547 and active fragments thereof.
- 25           4.           The composition of Claim 3, wherein the protein activated receptor comprises PAR-2.
- 30           5.           The composition of Claim 1, wherein the protein activated receptor comprises PAR-2 and wherein the wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1).

6. The composition of Claim 1, wherein the protein activated receptor comprises PAR-2 and wherein the wherein the protein, peptide, or biomolecule comprises ENMD 547.
- 5 7. The composition of Claim 1, further comprising a pharmaceutically acceptable carrier.
8. A method for inhibiting protein activated receptor activity in a subject comprising administering to said subject protein, peptide, biomolecule or active fragment thereof.
- 10 9. The method of Claim 8, wherein the protein activated receptor comprises PAR-1, PAR-2, PAR-3 or PAR-4.
- 15 10. The method of Claim 8, wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1), LIGKV (SEQ ID NO:2), KGIL (SEQ ID NO:3), KGI (SEQ ID NO:4), AGI (SEQ ID NO:5), IGA (SEQ ID NO:6), KGA (SEQ ID NO:7), KGA (SEQ ID NO:8), KAI (SEQ ID NO:9), IAK (SEQ ID NO:10), RGI (SEQ ID. NO:11), IGR (SEQ ID NO:12), Dab-GI (SEQ ID NO:13 ), Dap-GI (SEQ ID NO:14), IG-Dab (SEQ ID NO:15 ), IG-Dap (SEQ ID NO:16), LIG-Dab (SEQ ID NO:17), Dab-GIL (SEQ ID NO:18), LIG-Dap (SEQ ID NO:19), Dap-GIL (SEQ ID NO:20), LIG-Orn (SEQ ID NO:21), Orn-GIL (SEQ ID: 22), Orn-GI (SEQ ID NO:23), IG-Orn (SEQ ID NO:24), ENMD 545, ENMD 547 and active fragments thereof.
- 20 25 30 11. The method of Claim 8, wherein the protein activated receptor comprises PAR-2.
- 35 12. The method of Claim 8, wherein the protein activated receptor comprises PAR-2 and wherein the wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1).

13. The method of Claim 8, wherein the protein activated receptor comprises PAR-2 and wherein the wherein the protein, peptide, or biomolecule comprises ENMD 547.

5

14. The method of Claim 8, further comprising a pharmaceutically acceptable carrier.

15. A method for treating a disorder associated with abnormal protein activated receptor activity comprising administering to a subject in need of such treatment, a composition comprising a protein, peptide, biomolecule or active fragment thereof capable of inhibiting protein activated receptor activity.

15

16. The method of Claim 15, wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1), LIGKV (SEQ ID NO:2), KGIL (SEQ ID NO:3), KGI (SEQ ID NO:4), AGI (SEQ ID NO:5), IGA (SEQ ID NO:6), KGA (SEQ ID NO:7), KGA (SEQ ID NO:8), KAI (SEQ ID NO:9), IAK (SEQ ID NO:10), RGI (SEQ ID. NO:11), IGR (SEQ ID NO:12), Dab-GI (SEQ ID NO:13 ), Dap-GI (SEQ ID NO:14), IG-Dab (SEQ ID NO:15 ), IG-Dap (SEQ ID NO:16), LIG-Dab (SEQ ID NO:17), Dab-GIL (SEQ ID NO:18), LIG-Dap (SEQ ID NO:19), Dap-GIL (SEQ ID NO:20), LIG-Orn (SEQ ID NO:21), Orn-GIL (SEQ ID: 22), Orn-GI (SEQ ID NO:23), IG-Orn (SEQ ID NO:24), ENMD 545, ENMD 547 and active fragments thereof.

25

17. The method of Claim 15, wherein the disorder comprises angiogenic disease, undesirable neovascularization, inflammation, tumor growth, sepsis, neurogenic inflammatory pain, asthma, post operative ileus and cancer.

30

18. The method of Claim 17, wherein the disorder comprises inflammation and wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1).

5 19. The method of Claim 17, wherein the disorder comprises inflammation and wherein the protein, peptide, or biomolecule comprises ENMD 547.

10 20. The method of Claim 15 further comprising a pharmaceutically acceptable carrier.

15